Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours

Background: Plasma exposure of sunitinib shows large inter-individual variation. Therefore, a pharmacokinetic (PK) study was performed to determine safety and feasibility of sunitinib dosing based on PK levels. Methods: Patients were treated with sunitinib 37.5 mg once daily. At days 15 and 29 of tr...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2014-05, Vol.110 (10), p.2441-2449
Main Authors: Lankheet, N A G, Kloth, J S L, Gadellaa-van Hooijdonk, C G M, Cirkel, G A, Mathijssen, R H J, Lolkema, M P J K, Schellens, J H M, Voest, E E, Sleijfer, S, de Jonge, M J A, Haanen, J B A G, Beijnen, J H, Huitema, A D R, Steeghs, N
Format: Article
Language:English
Subjects:
631/67/1059
631/92/436/1729
Adult
Aged
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - blood
Antineoplastic Agents - pharmacokinetics
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer Research
Clinical Study
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug dosages
Drug Monitoring
Drug Resistance
Epidemiology
Fatigue - chemically induced
Feasibility Studies
Female
Gastrointestinal Diseases - chemically induced
Hematologic Diseases - chemically induced
Humans
Indoles - administration & dosage
Indoles - adverse effects
Indoles - blood
Indoles - pharmacokinetics
Male
Medical sciences
Middle Aged
Molecular Medicine
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Neoplasms - drug therapy
Neoplasms - enzymology
Nervous System Diseases - chemically induced
Oncology
Patients
Pharmacokinetics
Pilot Projects
Protein Kinase Inhibitors - administration & dosage
Protein Kinase Inhibitors - adverse effects
Protein Kinase Inhibitors - blood
Protein Kinase Inhibitors - pharmacokinetics
Pyrroles - administration & dosage
Pyrroles - adverse effects
Pyrroles - blood
Pyrroles - pharmacokinetics
Salvage Therapy
Therapeutic drug monitoring
Toxicity
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Plasma exposure of sunitinib shows large inter-individual variation. Therefore, a pharmacokinetic (PK) study was performed to determine safety and feasibility of sunitinib dosing based on PK levels. Methods: Patients were treated with sunitinib 37.5 mg once daily. At days 15 and 29 of treatment, plasma trough levels of sunitinib and N-desethyl sunitinib were measured. If the total trough level (TTL) was
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.2014.194